- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Lymphomas | Clinical
Future Directions for Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
July 23, 2021
Laurie Sehn, MD, discusses the unmet needs and future directions in the treatment of relapsed/refractory diffuse large B-cell lymphoma.
Novel Therapies in Development for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
July 23, 2021
A key opinion leader reviews novel therapies for diffuse large B-cell lymphoma.
Options for Second-Line Treatment in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
July 23, 2021
Dr Laurie Sehn reviews the NCCN guidelines for second-line therapy in relapsed/refractory diffuse large B-cell lymphoma and discusses the clinical trial data for a recently approved new treatment combination.
First-Line Therapy Options in Diffuse Large B-Cell Lymphoma
July 23, 2021
An expert hematologist-oncologist describes risk assessment for diffuse large B-cell lymphoma, as well as first-line therapy selection based on risk and other factors.
Case Presentation: A 76-Year-Old Man with Relapsed Diffuse Large B-Cell Lymphoma
July 23, 2021
Laurie Sehn, MD, presents the case of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma.
Exploring the Use of Tisagenlecleucel for Patients With Lymphoma
July 21, 2021
Stephen J. Schuster, MD, discusses tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma in the phase 2 Elara trial and the 5-year follow-up of a smaller CAR T-cell trial.
Epstein Barr Virus T-Cell Therapy Mitigates Challenges of CAR Treatments in Lymphoma
July 14, 2021
Encouraging findings from an ongoing phase 1 trial evaluating an off-the-shelf, allogeneic CD30-CAR Epstein Barr virus–specific T-cell therapy, evaluated in patients with lymphoma.
Ibrutinib Bests Chlorambucil in Elderly Patients with Treatment-Naïve CLL/SLL
July 01, 2021
Paul Barr, MD, discusses the results of the RESONATE-2, which evaluates efficacy of the Bruton’s tyrosine kinase inhibitor, ibrutinib versus chlorambucil in patients who are 65 years old or older with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Jacobson Outlines the Phase 2 ZUMA-5 Study
June 22, 2021
Caron A. Jacobson, MD, MMSc, discusses the design of the phase 2 ZUMA-5 trial, which evaluated the efficacy of axicabtagene ciloleucel in relapsed/refractory indolent Non-Hodgkin Lymphoma.
FDA Approval Sought for Copanlisib Plus Rituximab in Relapsed iNHL
June 21, 2021
A supplemental new drug application has been submitted to the FDA seeking approval for the combination of copanlisib and rituximab for the treatment of relapsed indolent B-cell non-Hodgkin’s Lymphoma and is outside of the FDA accelerated approved indication for the treatment of relapsed follicular lymphoma who have received at least 2 prior systemic therapies.